Oct. 18, 2012
-- A recent multi-disciplines research published on Clinical Cancer
Research showed that researchers of Bellvitge Biology Research Institution and Catalan Tumor Research Institution have developed a new drug that can test the drug effectiveness for ovarian cancer in terms of cisplatin-resistant.
They generated a preclinical model of ovarian cancer
after orthotopic implantation of a primary serous tumor in nude mice. This implantation method leaded to the specific human tumor and tumorexpansion model on histological and genetic level. However, the implantation so far hasn’tgot the specific human tumor effect, while those models were very important for developing individual cancer therapy. Then matched model of acquired cisplatin-resistant tumor version was successfully derived in mice. Effectiveness of lurbinectedin (PM01183) treatment, a novel marine-derived DNA minor groove covalent binder, was assessed in both preclinical models as a single and a combined-cisplatin agent.
In this research, they found the new experimental model and technology were also equally vital for developing the new testing drug—Lurbinectedin (PMO1183). The orthotopicimplantation on mice model can not only deepen the cancer research, but also help medical companies to develop new anti-cancer drug. Now the Lurbinectedinwas in the Phrase IIclinic trial.
origin : creative biomart